1
Clinical Trials associated with ALXN-2230A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Assess Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of ALXN2230 in Healthy Adult Participants
The primary objective of this study is to evaluate the safety and tolerability of single subcutaneous (SC) doses of ALXN2230 in healthy participants.
100 Clinical Results associated with ALXN-2230
100 Translational Medicine associated with ALXN-2230
100 Patents (Medical) associated with ALXN-2230
100 Deals associated with ALXN-2230